Archer Materials has strengthened its biochip ommercialisation pathway by improving the testing accuracy of the biosensor, making it more aligned with the United States Clinical Laboratory Improvement Amendments (CLIA) requirements for equivalent testing in a pathology lab.
Archer continues to develop the Biochip by using graphene and silicon based technologies.
Commenting on the Biochip progress, CEO Dr Simon Ruffell, mentioned:
"The Archer team has been working hard and recent engineering design changes have led to a significant increase in the Biosensor testing accuracy. The team has regularly achieved potassium measurement precision within 0.3 mM/L, in alignment with Clinical Laboratory Improvement Amendments (CLIA) requirements for equivalent testing in a pathology lab.
Our Biochip technology continues to progress strongly, and we see value in developing both graphene and silicon versions. Silicon offers an opportunity to reach market faster through existing manufacturing infrastructure, while graphene remains a key part of our future plans for a high-performance, next-generation device. This dual approach gives us the flexibility to meet market needs now and into the future."
Learn more about this latest development in our ASX announcement
Get the latest updates on our breakthrough technologies and research developments. Join thousands of researchers, investors, and technology enthusiasts.
